D. P. Andrew, M. Chang, J. Mcninch, S. T. Wathen, M. Rihanek et al., STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13, J. Immunol, vol.161, pp.5027-5038, 1998.

K. L. Asquith, H. S. Ramshaw, P. M. Hansbro, K. W. Beagley, A. F. Lopez et al., The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the regulation of the Th2 immunity and allergic airway inflammation, J. Immunol, vol.180, pp.1199-1206, 2008.

E. Bargagli, A. Mazzi, F. Mezzasalma, A. Perrone, C. Olivieri et al., The analysis of tryptase in serum of sarcoidosis patients, Inflammation, vol.32, pp.310-314, 2009.

M. Boggild, Immunosuppression followed by immunomodulation, J. Neurol. Sci, vol.277, pp.50-54, 2009.

S. Columba-cabezas, B. Serafini, E. Ambrosini, M. Sanchez, G. Penna et al., Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation, J. Neuroimmunol, vol.130, pp.10-21, 2002.

G. Comi, Treatment of multiple sclerosis: role of natalizumab, Neurol. Sci, vol.30, pp.155-158, 2009.

G. Comi, M. Filippi, and J. S. Wolinsky, European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group, Ann. Neurol, vol.49, pp.290-297, 2001.

N. De-stefano, M. Filippi, C. Confavreux, P. Vermersch, M. Simu et al., The results of two multicenter, open-label studies assessing efficacy, tolerability and safety of protiramer, a high molecular weight synthetic copolymeric mixture, in patients with relapsing-remitting multiple sclerosis, Mult. Scler, vol.15, pp.238-243, 2009.

S. L. Deshmane, S. Kremlev, S. Amini, and B. E. Sawaya, Monocyte chemoattractant protein 1 (MCP-1): an overview, J. Interferon Cytokine Res, vol.29, pp.313-326, 2009.

S. Dhib-jalbut, Glatiramer acetate (Copaxone®) therapy for multiple sclerosis, Pharmacol. Ther, vol.98, pp.245-255, 2003.

A. Dressel, D. Mirowska-guzel, C. Gerlach, and F. Wber, Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a, Acta Neurol. Scand, vol.116, pp.164-168, 2007.

S. Ebner, S. Hofer, V. A. Nguyen, C. Furhapter, M. Herold et al., A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern, J. Immunol, vol.168, pp.6199-6207, 2002.

R. Eri, K. N. Kodumudi, D. J. Summerlin, and M. Srinivasan, Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease, Inflamm. Bowel Dis, vol.14, pp.458-470, 2008.

F. D. Finkelman, Anaphylaxis: lessons from mouse models, J. Allergy Clin. Immunol, vol.120, pp.506-515, 2007.
DOI : 10.1016/j.jaci.2007.07.033

M. Fridkis-hareli, D. Teitelbaum, E. Gurevich, I. Pecht, C. Brautbar et al., Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigenpresenting cells-specificity and promiscuity, Proc. Natl. Acad. Sci. U. S. A, vol.91, pp.4872-4876, 1994.

M. Fridkis-hareli, L. Santambrogio, J. N. Stern, L. Fugger, C. Brosnan et al., Novel synthetic amino acid copolymers that inhibit autoantigen-specfic T cell responses and suppress experimental autoimmune encephalomyelitis, J. Clin. Investig, vol.109, pp.1635-1643, 2002.
DOI : 10.1172/jci0215402

URL : http://www.jci.org/articles/view/15402/files/pdf

L. Gauthier, K. J. Smith, J. Pyrdol, A. Kalandadze, J. L. Strominger et al., Expression and crystallization of the complex HLADR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein, Proc. Natl. Acad. Sci. U. S. A, vol.95, pp.828-839, 1998.

L. Gu, S. Tseng, R. M. Horner, C. Tam, M. Loda et al., Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1, Nature, vol.404, pp.407-411, 2000.

S. Herman, N. Zurgil, P. Langevitz, M. Ehrenfeld, and M. Deutsch, Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients, Clin. Exp. Rheumatol, vol.26, pp.317-323, 2008.

Z. Illés, J. N. Stern, J. Reddy, H. Waldner, M. P. Mycko et al., Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.749-760, 2004.

M. Inglese, J. H. Van-waesberghe, M. Rovaris, K. Beckmann, F. Barkhof et al., The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS, Neurology, vol.60, pp.853-860, 2003.

S. Jarius, R. Hohlfeld, and R. Voltz, Diagnosis and treatment of multiple sclerosis, Fortschr. Med, vol.145, p.95, 2003.

K. P. Johnson, B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, Neurology, vol.45, pp.1268-1276, 1995.

A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi et al., The chemokine system in diverse forms of macrophage activation and polarization, Trends Immunol, vol.25, pp.677-686, 2004.

V. Martinelli, M. Radaelli, L. Straffi, M. Rodegher, and G. Comi, Mitoxantrone: benefits and risks in multiple sclerosis patients, Neurol. Sci, vol.30, pp.167-170, 2009.

M. Maurer and E. Von-stebut, Macrophage inflammatory protein-1, Int. J. Biochem. Cell Biol, vol.36, pp.1882-1886, 2004.

A. Miller, S. Shapiro, R. Gershtein, A. Kinarty, H. Rawashdeh et al., Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation, J. Neuroimmunol, vol.92, pp.113-121, 1998.

T. Nakayama and M. Yamashita, Initiation and maintenance of Th2 cell identity, Curr. Opin. Immunol, vol.20, pp.265-271, 2008.

D. C. Newcomb, W. Zhou, M. L. Moore, K. Goleniewska, G. K. Hershey et al., A functional IL-13 receptor is expressed on polarized murine CD4 + Th17 cells and IL-13 signaling attenuates Th17 cytokine production, J. Immunol, vol.182, pp.5317-5321, 2009.

C. Papeix and C. Lubetzki, Monoclonal antibodies in multiple sclerosis, Med. Sci, vol.25, pp.1113-1115, 2009.

A. Prat, K. Biernacki, and J. P. Antel, Th1 and Th2 lymphocyte migration across the human BBB is specifically regulated by interferon beta and copolymer-1, J. Autoimmun, vol.24, pp.119-124, 2005.
DOI : 10.1016/j.jaut.2005.01.004

H. Saito, A. Kato, and K. Matsumoto, Role of mast cells in allergy, Nippon Rinsho, vol.67, pp.2083-2087, 2009.

A. Sanna, M. L. Fois, G. Arru, Y. M. Huang, H. Link et al., Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 ad IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis, Clin. Exp. Immunol, vol.143, pp.357-362, 2006.

J. N. Stern, Z. Illés, J. Reddy, D. B. Keskin, E. Sheu et al., Amelioration of proteolipid protein 139-151-induces encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms, Proc. Natl. Acad. Sci. U. S. A, vol.101, pp.743-754, 2004.
DOI : 10.1073/pnas.0403832101

URL : http://www.pnas.org/content/101/32/11743.full.pdf

D. Teitelbaum, A. Meshorer, T. Hirshfeld, R. Arnon, and M. Sela, Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide, Eur. J. Immunol, vol.1, pp.242-248, 1971.
DOI : 10.1002/eji.1830010406

H. Varkony, V. Weinstein, E. Klinger, J. Sterling, H. Cooperman et al., The glatiramoid class of immunomodulator drugs, Expert Opin. Pharmacother, vol.10, pp.657-668, 2009.
DOI : 10.1517/14656560902802877

J. S. Wolinsky, G. Comi, M. Filippi, D. Ladkani, S. Kadosh et al., Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained, Neurology, vol.59, pp.1284-1286, 2002.
DOI : 10.1212/wnl.59.8.1284

T. Ziemssen, O. Neuhaus, and R. Hohlfeld, Risk-benefit assessment of glatiramer acetate in multiple sclerosis, Drug Saf, vol.24, pp.979-990, 2001.
DOI : 10.2165/00002018-200124130-00005